` TECX (AVROBIO Inc) vs S&P 500 Comparison - Alpha Spread

TECX
vs
S&P 500

Over the past 12 months, TECX has significantly outperformed S&P 500, delivering a return of 54% compared to the S&P 500's 8% growth.

Stocks Performance
TECX vs S&P 500

Loading

Performance Gap
TECX vs S&P 500

Loading
TECX
S&P 500
Difference

Performance By Year
TECX vs S&P 500

Loading
TECX
S&P 500
Add Stock

Competitors Performance
AVROBIO Inc vs Peers

S&P 500
TECX
ABBV
AMGN
GILD
VRTX
Add Stock

AVROBIO Inc
Glance View

Market Cap
417.6m USD
Industry
Biotechnology

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.

TECX Intrinsic Value
7.55 USD
Overvaluation 66%
Intrinsic Value
Price
Back to Top